NGeneBio adjusts paid-in capital increase schedule
엔젠바이오
354200
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2445
Risk-adjusted indicator based on 2445 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Original Final Issuance Price Date: August 10, 2026
- • Amended Final Issuance Price Date: September 4, 2026
- • Original Subscription Start Date: August 13, 2026
- • Amended Subscription Start Date: September 9, 2026
- • Original Payment Date: August 24, 2026
- • Amended Payment Date: September 17, 2026
- • Original New Share Listing Date: September 4, 2026
- • Amended New Share Listing Date: October 2, 2026
- • Pre-capital reduction shares: 26,809,750 Shares
- • New share allocation ratio per share: 0.8000820895 Shares
- • Discount rate for issuance price: 25%
AI Analysis Summary
NGeneBio Co., Ltd. has filed an amendment to its Material Fact Report regarding a paid-in capital increase. The key change involves a delay in the schedule, with the final issuance price determination date moved from August 10, 2026, to September 4, 2026. The subscription period for existing shareholders is now September 9-10, 2026, and the payment date is September 17, 2026. The new shares are expected to be listed on October 2, 2026. The company previously announced a capital reduction (3-for-1 reverse stock split) effective June 24, 2026, from 26,809,750 shares. The new share allocation ratio is 0.8000820895 shares per existing share, with a 25% discount rate applied to the issuance price. This amendment primarily concerns a timeline adjustment and does not alter the fundamental dilution impact of the capital increase.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.